A retrospective study shows GLP-1s lower colorectal cancer risk in a large population, suggesting a significant preventive option.
In a large retrospective study, those taking a glucagon-like peptide 1 (GLP-1) receptor agonist drug were 36% less likely to develop colorectal cancer than those taking aspirin. Although the benefit seen for any one person was small, thousands could potentially see a benefit given the large number of people taking GLP-1s.d
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: